Celgene Ducks Teva Unit's Breast-Cancer Drug IP Claims

Law360, Los Angeles (March 18, 2014, 8:49 PM EDT) -- A Massachusetts federal judge entered an order Tuesday clearing Celgene Corp. of allegations that its antitumor drug Abraxane infringed a Teva Pharmaceutical Industries Ltd. unit's patent covering the drug's active ingredient, after the parties agreed his claim construction ruling precluded an infringement finding.

The judge approved a stipulated final judgment of noninfringement after specialty pharmaceutical company Acusphere Inc. and its exclusive licensee Cephalon Inc. said Abraxane didn't infringe any valid claim of U.S. Patent Number RE40,493 under the judge's December construction decision.

"While each party reserves...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.